<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article xml:lang="en" article-type="research-article" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">660</journal-id>
        <journal-id journal-id-type="pmc-domain">jco</journal-id>
        <journal-id journal-id-type="publisher-id">JCO</journal-id>
        <journal-title-group>
          <journal-title>Journal of Clinical Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0732-183X</issn>
        <issn pub-type="epub">1527-7755</issn>
        <publisher>
          <publisher-name>American Society of Clinical Oncology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8713593</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8713593.1</article-id>
        <article-id pub-id-type="pmcaid">8713593</article-id>
        <article-id pub-id-type="pmcaiid">8713593</article-id>
        <article-id pub-id-type="pmid">34618601</article-id>
        <article-id pub-id-type="doi">10.1200/JCO.21.00807</article-id>
        <article-id pub-id-type="publisher-id">JCO.21.00807</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>ORIGINAL REPORTS</subject>
            <subj-group>
              <subject>Hematologic Malignancy</subject>
            </subj-group>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic
Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease
Cohort of the Randomized Phase II CAPTIVATE Study</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7357-270X</contrib-id>
            <name name-style="western">
              <surname>Wierda</surname>
              <given-names initials="WG">William G.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff1" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="con1" ref-type="fn" />
            <xref rid="cor1" ref-type="corresp" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Allan</surname>
              <given-names initials="JN">John N.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff2" ref-type="aff">
              <sup>2</sup>
            </xref>
            <xref rid="con2" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5292-8298</contrib-id>
            <name name-style="western">
              <surname>Siddiqi</surname>
              <given-names initials="T">Tanya</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff3" ref-type="aff">
              <sup>3</sup>
            </xref>
            <xref rid="con3" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0064-4549</contrib-id>
            <name name-style="western">
              <surname>Kipps</surname>
              <given-names initials="TJ">Thomas J.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff4" ref-type="aff">
              <sup>4</sup>
            </xref>
            <xref rid="con4" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0308-6458</contrib-id>
            <name name-style="western">
              <surname>Opat</surname>
              <given-names initials="S">Stephen</given-names>
            </name>
            <degrees>MBBS</degrees>
            <xref rid="aff5" ref-type="aff">
              <sup>5</sup>
            </xref>
            <xref rid="con5" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tedeschi</surname>
              <given-names initials="A">Alessandra</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff6" ref-type="aff">
              <sup>6</sup>
            </xref>
            <xref rid="con6" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Badoux</surname>
              <given-names initials="XC">Xavier C.</given-names>
            </name>
            <degrees>MBBS</degrees>
            <xref rid="aff7" ref-type="aff">
              <sup>7</sup>
            </xref>
            <xref rid="con7" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5811-1331</contrib-id>
            <name name-style="western">
              <surname>Kuss</surname>
              <given-names initials="BJ">Bryone J.</given-names>
            </name>
            <degrees>MBBS, PhD</degrees>
            <xref rid="aff8" ref-type="aff">
              <sup>8</sup>
            </xref>
            <xref rid="con8" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jackson</surname>
              <given-names initials="S">Sharon</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff9" ref-type="aff">
              <sup>9</sup>
            </xref>
            <xref rid="con9" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Moreno</surname>
              <given-names initials="C">Carol</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff10" ref-type="aff">
              <sup>10</sup>
            </xref>
            <xref rid="con10" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jacobs</surname>
              <given-names initials="R">Ryan</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff11" ref-type="aff">
              <sup>11</sup>
            </xref>
            <xref rid="con11" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5745-8125</contrib-id>
            <name name-style="western">
              <surname>Pagel</surname>
              <given-names initials="JM">John M.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff12" ref-type="aff">
              <sup>12</sup>
            </xref>
            <xref rid="con12" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6724-290X</contrib-id>
            <name name-style="western">
              <surname>Flinn</surname>
              <given-names initials="I">Ian</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff13" ref-type="aff">
              <sup>13</sup>
            </xref>
            <xref rid="con13" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pak</surname>
              <given-names initials="Y">Yvonne</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
            <xref rid="con14" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zhou</surname>
              <given-names initials="C">Cathy</given-names>
            </name>
            <degrees>MS</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
            <xref rid="con15" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Szafer-Glusman</surname>
              <given-names initials="E">Edith</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
            <xref rid="con16" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9711-5052</contrib-id>
            <name name-style="western">
              <surname>Ninomoto</surname>
              <given-names initials="J">Joi</given-names>
            </name>
            <degrees>PharmD</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
            <xref rid="con17" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dean</surname>
              <given-names initials="JP">James P.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
            <xref rid="con18" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>James</surname>
              <given-names initials="DF">Danelle F.</given-names>
            </name>
            <degrees>MD, MAS</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
            <xref rid="con19" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3750-7342</contrib-id>
            <name name-style="western">
              <surname>Ghia</surname>
              <given-names initials="P">Paolo</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff15" ref-type="aff">
              <sup>15</sup>
            </xref>
            <xref rid="con20" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9759-5017</contrib-id>
            <name name-style="western">
              <surname>Tam</surname>
              <given-names initials="CS">Constantine S.</given-names>
            </name>
            <degrees>MBBS, MD</degrees>
            <xref rid="aff16" ref-type="aff">
              <sup>16</sup>
            </xref>
            <xref rid="con21" ref-type="fn" />
          </contrib>
          <aff id="aff1">
            <label>
              <sup>1</sup>
            </label>Department of Leukemia, University of
Texas MD Anderson Cancer Center, Houston, TX</aff>
          <aff id="aff2">
            <label>
              <sup>2</sup>
            </label>Weill Cornell Medicine, New York, NY</aff>
          <aff id="aff3">
            <label>
              <sup>3</sup>
            </label>City of Hope National Medical Center,
Duarte, CA</aff>
          <aff id="aff4">
            <label>
              <sup>4</sup>
            </label>UCSD Moores Cancer Center, San Diego,
CA</aff>
          <aff id="aff5">
            <label>
              <sup>5</sup>
            </label>Monash University, Clayton, VIC,
Australia</aff>
          <aff id="aff6">
            <label>
              <sup>6</sup>
            </label>ASST Grande Ospedale Metropolitano
Niguarda, Milan, Italy</aff>
          <aff id="aff7">
            <label>
              <sup>7</sup>
            </label>Ministry of Health, Kogarah, NSW,
Australia</aff>
          <aff id="aff8">
            <label>
              <sup>8</sup>
            </label>Flinders University and Medical Centre,
Bedford Park, SA, Australia</aff>
          <aff id="aff9">
            <label>
              <sup>9</sup>
            </label>Middlemore Hospital, Auckland, New
Zealand</aff>
          <aff id="aff10">
            <label>
              <sup>10</sup>
            </label>Hospital de la Santa Creu I Sant Pau,
Autonomous University of Barcelona, Barcelona, Spain</aff>
          <aff id="aff11">
            <label>
              <sup>11</sup>
            </label>Levine Cancer Institute, Charlotte,
NC</aff>
          <aff id="aff12">
            <label>
              <sup>12</sup>
            </label>Swedish Cancer Institute Center for
Blood Disorders and Stem Cell Transplantation, Seattle, WA</aff>
          <aff id="aff13">
            <label>
              <sup>13</sup>
            </label>Sarah Cannon Research
Institute/Tennessee Oncology, Nashville, TN</aff>
          <aff id="aff14">
            <label>
              <sup>14</sup>
            </label>Pharmacyclics LLC, an AbbVie Company,
Sunnyvale, CA</aff>
          <aff id="aff15">
            <label>
              <sup>15</sup>
            </label>Università Vita-Salute San Raffaele
and IRCCS Ospedale San Raffaele, Milan, Italy</aff>
          <aff id="aff16">
            <label>
              <sup>16</sup>
            </label>Peter MacCallum Cancer Center and St
Vincent's Hospital and the University of Melbourne, Melbourne, VIC,
Australia</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1">William G. Wierda, MD, PhD, Department of Leukemia, University of
Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX
77030; e-mail: <email>wwierda@mdanderson.org</email>.</corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>1</day>
          <month>12</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>07</day>
          <month>10</month>
          <year>2021</year>
        </pub-date>
        <volume>39</volume>
        <issue>34</issue>
        <issue-id pub-id-type="pmc-issue-id">394217</issue-id>
        <fpage>3853</fpage>
        <lpage>3865</lpage>
        <self-uri content-type="pmc-pdf" ns0:href="jco-39-3853.pdf" />
        <self-uri ns0:href="jco-39-3853.pdf" />
        <abstract>
          <title>PURPOSE</title>
          <p>CAPTIVATE (<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT02910583" ext-link-type="uri">NCT02910583</ext-link>), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of
first-line ibrutinib plus venetoclax treatment in patients with chronic
lymphocytic leukemia (CLL).</p>
          <sec>
            <title>METHODS</title>
            <p>Previously untreated CLL patients age &lt; 70 years received three cycles
of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax.
Patients in the MRD cohort who met the stringent random assignment criteria
for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1
to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD
Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or
ibrutinib plus venetoclax. Primary end point was 1-year disease-free
survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD
population. Secondary end points included response rates, uMRD, and
safety.</p>
          </sec>
          <sec>
            <title>RESULTS</title>
            <p>One hundred sixty-four patients initiated three cycles of ibrutinib lead-in.
After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were
75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD
were randomly assigned to receive placebo (n = 43) or ibrutinib (n
= 43); patients with uMRD Not Confirmed were randomly assigned to
ibrutinib (n = 31) or ibrutinib plus venetoclax (n = 32). Median
follow-up was 31.3 months. One-year DFS rate was not significantly different
between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI,
–1.6 to 10.9]; <italic toggle="yes">P</italic> = .15) in the Confirmed uMRD
population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%)
with high tumor lysis syndrome risk at baseline shifted to medium or low
tumor lysis syndrome risk categories. Adverse events were most frequent
during the first 6 months of ibrutinib plus venetoclax and generally
decreased over time.</p>
          </sec>
          <sec>
            <title>CONCLUSION</title>
            <p>The 1-year DFS rate of 95% in placebo-randomly assigned patients with
Confirmed uMRD suggests the potential for fixed-duration treatment with this
all-oral, once-daily, chemotherapy-free regimen in first-line CLL.</p>
          </sec>
        </abstract>
        <counts>
          <fig-count count="6" />
          <table-count count="1" />
          <equation-count count="0" />
          <ref-count count="36" />
          <page-count count="0" />
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-license-ref</meta-name>
            <meta-value>CC BY-NC-ND</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec sec-type="intro">
        <title>INTRODUCTION</title>
        <p>Targeted therapies that antagonize B-cell receptor signaling by inhibiting the Bruton
tyrosine kinase (BTK) pathway and restore apoptosis by inhibiting the antiapoptotic
protein B-cell lymphoma 2 (BCL-2) have remarkably improved outcomes for patients
with chronic lymphocytic leukemia (CLL).<sup>
            <xref rid="b1" ref-type="bibr">1</xref>
          </sup> Ibrutinib, a once-daily BTK inhibitor, is the only targeted
therapy to demonstrate both improved progression-free survival (PFS) and overall
survival (OS) over standard chemotherapy and/or chemoimmunotherapy regimens in
randomized phase III studies in previously untreated CLL or small lymphocytic
lymphoma (SLL; RESONATE-2; ECOG1912).<sup>
            <xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref>
          </sup> Venetoclax is an
oral BCL-2 inhibitor approved for the treatment of CLL and SLL as a single agent or
combined with anti-CD20 monoclonal antibodies (rituximab or obinutuzumab).<sup>
            <xref rid="b4" ref-type="bibr">4</xref>
          </sup> Venetoclax provides deep responses
with undetectable minimal residual disease (uMRD) rates in bone marrow (BM) of 16%
with single-agent venetoclax in relapsed or refractory CLL<sup>
            <xref rid="b5" ref-type="bibr">5</xref>-<xref rid="b8" ref-type="bibr">8</xref>
          </sup> and 57% with
venetoclax plus obinutuzumab in previously untreated CLL.<sup>
            <xref rid="b9" ref-type="bibr">9</xref>
          </sup> Continuous ibrutinib affords survival benefit, but
there is increasing desire for convenient, all-oral, time-limited treatment options
that may be safely administered in the outpatient setting.</p>
        <boxed-text id="B1" position="anchor" orientation="portrait">
          <sec sec-type="context-box">
            <title>CONTEXT</title>
            <p>
              <list list-type="simple">
                <list-item>
                  <p>
                    <bold>Key Objective</bold>
                  </p>
                </list-item>
                <list-item>
                  <p>Continuous single-agent ibrutinib affords survival benefit in the
first-line treatment of chronic lymphocytic leukemia (CLL), but
there is increasing desire for convenient, all-oral,
time-limited treatment options that may be safely administered
in the outpatient setting. This randomized phase II study
evaluated minimal residual disease (MRD)-guided treatment
discontinuation following combination treatment with ibrutinib
plus venetoclax in patients with previously untreated CLL.</p>
                </list-item>
                <list-item>
                  <p>
                    <bold>Knowledge Generated</bold>
                  </p>
                </list-item>
                <list-item>
                  <p>One-year disease-free survival rates after random assignment were
not significantly different between placebo- and
ibrutinib-randomly assigned patients with confirmed undetectable
MRD following 12 cycles of combined ibrutinib plus venetoclax.
Progression-free survival rates were ≥ 95% across all
MRD-guided randomized treatment arms.</p>
                </list-item>
                <list-item>
                  <p>
                    <bold>Relevance (<italic toggle="yes">J.W. Friedberg</italic>)</bold>
                  </p>
                </list-item>
                <list-item>
                  <p>These results show the potential for fixed-duration treatment
with ibrutinib plus venetoclax, using MRD guidance. Ongoing
randomized trials are comparing fixed-duration therapy to
continuous Bruton tyrosine kinase inhibitor therapy in patients
with CLL.*</p>
                </list-item>
                <list-item>
                  <p>*Relevance section written by <italic toggle="yes">JCO</italic>
Editor-in-Chief Jonathan W. Friedberg, MD.</p>
                </list-item>
              </list>
            </p>
          </sec>
        </boxed-text>
        <p>Ibrutinib plus venetoclax provides synergistic and complementary antitumor activity
beyond peripheral blood (PB) and BM compartments.<sup>
            <xref rid="b10" ref-type="bibr">10</xref>-<xref rid="b14" ref-type="bibr">14</xref>
          </sup> In
preclinical CLL models, combined ibrutinib plus venetoclax resulted in greater
antitumor activity than either agent alone.<sup>
            <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b14" ref-type="bibr">14</xref>
          </sup> Ibrutinib and venetoclax have complementary
mechanisms of action: ibrutinib inhibition of BTK enhances dependence of CLL cells
on BCL-2 through reductions in MCL-1 and BCL-X<sub>L</sub>.<sup>
            <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref>
          </sup> In addition to inhibiting CLL cell proliferation and
survival, ibrutinib mobilizes CLL cells from protective microenvironment niches and
disease compartments into circulation by blocking retention signals, rendering cells
more susceptible to apoptosis, which is notably accelerated by addition of
venetoclax.<sup>
            <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b15" ref-type="bibr">15</xref>
          </sup> Recent clinical
studies with ibrutinib plus venetoclax demonstrated high uMRD rates in both PB and
BM in patients with CLL or SLL.<sup>
            <xref rid="b16" ref-type="bibr">16</xref>-<xref rid="b20" ref-type="bibr">20</xref>
          </sup>
        </p>
        <p>With time-limited therapies, uMRD is an important end point that appears predictive
of durable efficacy outcomes. In patients treated with chemoimmunotherapy, such as
fludarabine, cyclophosphamide, and rituximab (FCR), uMRD status correlated with
longer PFS and OS, regardless of depth of clinical response per International
Workshop on CLL (iwCLL) criteria.<sup>
            <xref rid="b21" ref-type="bibr">21</xref>-<xref rid="b23" ref-type="bibr">23</xref>
          </sup> uMRD at the end
of combination venetoclax and rituximab in relapsed or refractory CLL was also
predictive of longer PFS.<sup>
            <xref rid="b24" ref-type="bibr">24</xref>
          </sup>
Increasing MRD clearance with targeted combinations is anticipated to lead to longer
PFS and potentially OS.</p>
        <p>In CAPTIVATE, we investigated combined ibrutinib plus venetoclax in first-line
treatment of CLL or SLL. We report primary analysis results from the CAPTIVATE MRD
cohort evaluating disease-free survival (DFS) and treatment-free remission.</p>
      </sec>
      <sec sec-type="methods">
        <title>METHODS</title>
        <sec sec-type="subjects">
          <title>Study Design and Patients</title>
          <p>CAPTIVATE is a multicenter, international, randomized, phase II study conducted
at 35 sites (Data Supplement, online only). The study comprised two cohorts: the
MRD cohort and a separate fixed-duration (FD) cohort (enrolled after the MRD
cohort and to be reported subsequently). The study was conducted in accordance
with International Conference on Harmonisation guidelines for Good Clinical
Practice and principles of the Declaration of Helsinki. The Protocol (online
only) was approved by institutional review boards or independent ethics
committees of all participating institutions. All patients provided written
informed consent. This study is registered with ClinicalTrials.gov (<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT02910583" ext-link-type="uri">NCT02910583</ext-link>).</p>
          <p>Eligible patients were age ≥ 18 to &lt; 70 years with previously
untreated CLL or SLL requiring treatment per iwCLL criteria<sup>
              <xref rid="b25" ref-type="bibr">25</xref>
            </sup> and had measurable nodal
disease by computed tomography; Eastern Cooperative Oncology Group performance
status 0-1; and adequate hepatic, renal, and hematologic function. Patients with
known allergy to xanthine oxidase inhibitors and/or rasburicase were excluded
because of requirement for tumor lysis syndrome (TLS) prophylaxis per venetoclax
prescribing information.<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup>
          </p>
        </sec>
        <sec>
          <title>Treatment and Random Assignment</title>
          <p>Patients in the MRD cohort received treatment during two phases: a
prerandomization phase followed by an MRD-guided randomization phase (Data
Supplement). During the prerandomization phase, patients received single-agent
oral ibrutinib (420 mg once daily) lead-in for three cycles followed by
ibrutinib plus oral venetoclax (target dose 400 mg once daily after standard
5-week ramp-up, with TLS prophylaxis and monitoring per venetoclax prescribing
information)<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup> for 12
cycles. Each cycle was 28 days. TLS risk categories were based on tumor burden
(Data Supplement).<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup> Patients in
the high-risk category for TLS (≥ 1 lymph node lesion ≥ 10 cm in
longest diameter, or ≥ 1 lesion ≥ 5 cm plus circulating
lymphocytes &gt; 25 × 10<sup>9</sup>/L) were hospitalized during the
first 24-48 hours of venetoclax treatment for more rigorous TLS monitoring and
prophylaxis.<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup>
Hospitalization was also recommended for patients with medium TLS risk and
creatinine clearance &lt; 80 mL/min.<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup>
          </p>
          <p>Patients who completed the three-cycle ibrutinib lead-in and then 12 cycles of
ibrutinib plus venetoclax continued one additional cycle of ibrutinib plus
venetoclax, during which MRD status was confirmed and tumor response was
assessed; eligible patients were then randomly assigned to subsequent treatment
according to MRD status (stratified by immunoglobulin heavy variable [IGHV] gene
mutation status). Patients with Confirmed uMRD (defined as &lt; 1 CLL cell per
10,000 leukocytes, serially over ≥ 2 assessments ≥ 3 months apart,
and in both PB and BM) (Data Supplement) were randomly assigned 1:1 to
double-blinded treatment with placebo or ibrutinib until confirmed MRD relapse
(increase to ≥ 1 CLL cell per 100 leukocytes, confirmed on two separate
occasions) or disease progression. Patients who did not meet the strict
Confirmed uMRD definition (ie, uMRD Not Confirmed population) were randomly
assigned 1:1 to open-label treatment with single-agent ibrutinib or continued
ibrutinib plus venetoclax (maximum 2 years overall duration for venetoclax)
until disease progression or unacceptable toxicity.</p>
        </sec>
        <sec>
          <title>Outcomes and Assessments</title>
          <p>The primary end point was 1-year DFS rate in the Confirmed uMRD population.
One-year DFS was defined as absence of MRD relapse, progression, or death at
least 1 year after random assignment. Secondary end points were uMRD rates in PB
and BM, overall response rate per investigator assessment using 2008 iwCLL
criteria,<sup>
              <xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b26" ref-type="bibr">26</xref>
            </sup> complete response (CR) rate
(including CR with incomplete BM recovery [CRi]), duration of response, TLS risk
category reduction (proportion of patients at high risk for TLS after ibrutinib
lead-in <italic toggle="yes">v</italic> baseline), PFS, OS, pharmacokinetics of ibrutinib and
venetoclax in combination, and safety and tolerability (Data Supplement).</p>
          <p>Assessments included MRD status by flow cytometry and clinical response using
physical examination, laboratory evaluations, and radiographic evaluation (Data
Supplement). Safety was evaluated at every visit. TLS risk per US prescribing
information for venetoclax<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup> was
assessed at baseline and before venetoclax initiation, and limited
pharmacokinetic sampling was performed (Data Supplement).</p>
        </sec>
        <sec>
          <title>Statistical Analysis</title>
          <p>Sample size was calculated based on the primary end point (1-year DFS rate) with
placebo versus ibrutinib in patients with Confirmed uMRD. Assuming a 40% uMRD
rate at random assignment, enrollment of 150 patients would ensure random
assignment of 60 patients with Confirmed uMRD. This would provide approximately
80% power to detect a 30% difference for continued ibrutinib versus placebo at a
two-sided significance level of 0.05.</p>
          <p>Efficacy and safety were evaluated in all patients who received ≥ 1 dose
of study treatment. Time-to-event end points, including 1-year DFS rates, were
estimated using the Kaplan-Meier method. Between-arm difference in 1-year DFS
rates was tested by Z test with standard error of each arm computed based on
Greenwood's formula. Pharmacokinetics were evaluated using noncompartmental
analysis. Other efficacy end points and adverse events (AEs) were summarized
descriptively. 95% CIs for response rates were estimated based on the exact
binomial distribution.</p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>RESULTS</title>
        <sec sec-type="subjects">
          <title>Patient Characteristics</title>
          <p>Among 164 enrolled patients, median age was 58 years (range, 28-69 years). Most
patients had high-risk disease features, including del(17p) (16%), del(11q)
(17%), del(17p) or <italic toggle="yes">TP53</italic> mutation (20%), complex karyotype
(19%), <italic toggle="yes">TP53</italic> mutation (12%), and unmutated IGHV gene (60%; Table
<xref rid="tbl1" ref-type="table">1</xref>). Baseline characteristics by
MRD-guided randomized treatment arm are shown in the Data Supplement.</p>
          <table-wrap position="float" id="tbl1" orientation="portrait">
            <label>TABLE 1.</label>
            <caption>
              <p>Patient Demographics and Disease Characteristics at Baseline</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g002.jpg" />
          </table-wrap>
        </sec>
        <sec>
          <title>Prerandomization Phase: Disposition and Efficacy</title>
          <p>All patients initiated ibrutinib lead-in and 159 received ibrutinib plus
venetoclax (Fig <xref rid="fig1" ref-type="fig">1</xref>). Overall, 148 of 164
patients (90%) completed planned prerandomization treatment (Fig <xref rid="fig1" ref-type="fig">1</xref>); see the Data Supplement for all
progressive disease events. Fifteen patients were ineligible for random
assignment because of discontinuation of one or both study drugs (Fig <xref rid="fig1" ref-type="fig">1</xref>).</p>
          <fig position="float" id="fig1" fig-type="figure" orientation="portrait">
            <label>FIG 1.</label>
            <caption>
              <p>Patient flow and disposition. AEs, adverse events; MRD, minimal residual
disease; PD, progressive disease; uMRD, undetectable minimal residual
disease.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g003.jpg" />
          </fig>
          <p>During the prerandomization phase, 75% (123 of 164) and 68% (112 of 164) of
all-treated patients achieved a best MRD response of uMRD in PB and BM,
respectively (75% [123 of 163] and 72% [112 of 156] of evaluable patients,
respectively) (Fig <xref rid="fig2" ref-type="fig">2</xref>A). Among patients
with uMRD in PB prerandomization with matched BM sample, 94% had uMRD in both
compartments. High uMRD rates in BM ranging from 56% to 79% were observed across
patient subgroups based on clinical and biologic features, including those with
high-risk disease features (Fig <xref rid="fig2" ref-type="fig">2</xref>B).
Response was achieved in 159 of 164 patients (overall response rate, 97%; 95%
CI, 93 to 99) with CR including CRi in 76 of 164 (46%; 95% CI, 39 to 54). In
patients with best response of CR including CRi, 83% (63 of 76) achieved PB uMRD
and 80% (61 of 76) achieved BM uMRD; in patients with a best response of partial
response (PR) or nodular PR, corresponding rates were 72% (60 of 83) and 61% (51
of 83), respectively.</p>
          <fig position="float" id="fig2" fig-type="figure" orientation="portrait">
            <label>FIG 2.</label>
            <caption>
              <p>MRD response during the prerandomization phase. (A) MRD levels serially
over time in PB and best MRD response in PB and BM. (B) Forest plot of
undetectable MRD in BM across patient subgroups by baseline
characteristics. (C) Best MRD response of the prerandomization phase in
all-treated patients and according to Confirmed uMRD status in patients
eligible for random assignment. <sup>a</sup>BM MRD assessment was
scheduled after completion of 12 cycles of combination treatment (cycle
16). <sup>b</sup>Per Dohner hierarchy. <sup>c</sup>Patients without
available samples (PB, n = 1; BM, n = 8) were counted as
having detectable MRD. BM, bone marrow; CLL, chronic lymphocytic
leukemia; ECOG PS, Eastern Cooperative Oncology Group performance
status; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin
heavy variable; MRD, minimal residual disease; PB, peripheral blood;
uMRD, undetectable minimal residual disease.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g004.jpg" />
          </fig>
          <p>Among 149 patients eligible for random assignment, 86 patients met Confirmed uMRD
criteria for random assignment (best uMRD rates of 100% in both PB and BM
prerandomization) (Fig <xref rid="fig2" ref-type="fig">2</xref>C). The remaining
63 patients not meeting strict criteria of Confirmed uMRD for random assignment
(Data Supplement) still achieved best uMRD rates of 48% (30 of 63) in PB and 32%
(20 of 63) in BM prerandomization (Fig <xref rid="fig2" ref-type="fig">2</xref>C).</p>
          <p>Tumor debulking with three cycles of ibrutinib<sup>
              <xref rid="b27" ref-type="bibr">27</xref>
            </sup> (reductions in lymph node diameter and
absolute lymphocyte count) (Data Supplement) led to substantial reduction in TLS
risk category. Together, 36 of 40 patients (90%) with high TLS risk at baseline
shifted to medium or low TLS risk categories after ibrutinib lead-in and 4 of
164 (2%) remained at high TLS risk (Fig <xref rid="fig3" ref-type="fig">3</xref>); no patients with medium or low TLS risk shifted to high-risk
category. The proportion of patients with hospitalization indicated for TLS
monitoring decreased from 47% (77 of 164) at baseline to 18% (30 of 164) after
ibrutinib lead-in. Overall, 131 of 159 patients (82%) initiated venetoclax
without hospitalization. Rasburicase was used per investigator discretion for
treatment of hyperuricemia in 1 of 164 (1%) patients and as TLS prophylaxis in
10 of 164 (6%) patients.</p>
          <fig position="float" id="fig3" fig-type="figure" orientation="portrait">
            <label>FIG 3.</label>
            <caption>
              <p>Impact of single-agent ibrutinib lead-in on TLS risk category. Shown are
TLS risk categories at baseline and after ibrutinib lead-in in the
prerandomization phase. TLS, tumor lysis syndrome.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g005.jpg" />
          </fig>
        </sec>
        <sec>
          <title>Prerandomization Phase: Safety and Pharmacokinetics</title>
          <p>Median treatment duration in the prerandomization phase was 14.7 months (range,
0.5-22.7 months) (Data Supplement). The most common treatment-emergent AEs among
164 patients treated during the prerandomization phase were diarrhea (71%, n
= 116), nausea (45%, n = 74), and neutropenia (43%, n = 70) (Data
Supplement). Most diarrhea events and all nausea events were grade 1 or 2. The
most common grade 3 or 4 AEs were neutropenia (35%, n = 58), hypertension
(8%, n = 13), thrombocytopenia (5%, n = 9), and diarrhea (5%, n =
8) (Data Supplement). No fatal AEs occurred. Serious AEs of any grade occurred
in 35 patients (21%) (Data Supplement). Atrial fibrillation of any grade
occurred in 12 patients (7%) and was grade ≥ 3 in three (2%). Major
hemorrhage occurred in two patients (1%). Grade ≥ 3 infections occurred
in 14 patients (9%) and febrile neutropenia occurred in three (2%). No clinical
TLS occurred. Laboratory TLS per Howard criteria<sup>
              <xref rid="b28" ref-type="bibr">28</xref>
            </sup> occurred in one patient categorized as low
risk for TLS who did not receive Protocol-specified oral hydration and
allopurinol; abnormalities spontaneously resolved without dose modification,
clinical sequelae, or hospitalization.</p>
          <p>AEs led to dose reductions of ibrutinib in 24 patients (15%) and venetoclax in 16
patients (10%) before random assignment. AEs led to discontinuation of ibrutinib
in 10 patients (6%) and venetoclax in six patients (4%). Two patients with grade
3 or 4 cardiac arrest discontinued both ibrutinib and venetoclax; no other AEs
led to discontinuation of either study drug in &gt; 1 patient, and no patients
discontinued because of infections. Diarrhea, neutropenia, and thrombocytopenia
were rarely associated with dose reductions (1%-4% of patients) or
discontinuations. Forty-eight patients (29%) received neutrophil growth factor
at investigator discretion per local standards of care.</p>
          <p>There was no change in ibrutinib mean plasma area under the curve (n = 112)
when coadministered with venetoclax (660 ng·h/mL) versus that observed
during single-agent ibrutinib lead-in (677 ng·h/mL). Venetoclax mean plasma
area under the curve (n = 151) was higher when coadministered with
ibrutinib (58.6 µg·h/mL) than that previously reported for
single-agent venetoclax 400 mg/d (32.8 µg·h/mL), but was within the
range observed in doses previously studied (150-800 mg/d).<sup>
              <xref rid="b4" ref-type="bibr">4</xref>
            </sup> Pharmacokinetic-safety analyses
revealed no association between exposure and AEs (data not shown).</p>
        </sec>
        <sec>
          <title>Randomized Phase: Efficacy and Safety in Confirmed uMRD Population</title>
          <p>The primary end point of DFS rate 1 year after random assignment was not
significantly different for patients with Confirmed uMRD randomly assigned to
placebo (95%) versus ibrutinib (100%; arm difference: 4.7% [95% CI, –1.6
to 10.9]; <italic toggle="yes">P</italic> = .15) (Fig <xref rid="fig4" ref-type="fig">4</xref>). With a median follow-up of 31.3 months (16.6 months after random
assignment), there were three (7%) DFS events (disease progression, n = 2;
MRD relapse, n = 1) in the placebo arm and no events in the ibrutinib arm.
No additional DFS events were observed with additional follow-up (Data
Supplement). Estimated 30-month PFS rates (from first dose of study treatment)
were 95% (95% CI, 83 to 99) with placebo and 100% (95% CI, 100 to 100) with
ibrutinib (Data Supplement). Modest CR including CRi rate improvements (5%-9%)
were observed postrandomization in both arms (Data Supplement). At random
assignment, uMRD in PB and BM was 100%; at 12 cycles postrandomization, uMRD was
84% (36 of 43) in PB and 81% (35 of 43) in BM with placebo, and 77% (33 of 43)
in both PB and BM with ibrutinib.</p>
          <fig position="float" id="fig4" fig-type="figure" orientation="portrait">
            <label>FIG 4.</label>
            <caption>
              <p>Disease-free survival. Kaplan-Meier estimates of DFS by randomized
treatment arm in the Confirmed uMRD population. Tick marks indicate
patients with censored data. Patients who did not experience a DFS event
were censored by the last MRD sample date with a valid result or the
date of last adequate disease assessment after random assignment,
whichever occurred earlier. <sup>a</sup>The three DFS events in the
placebo arm were disease progression in two patients and MRD relapse in
one patient; of the two patients with disease progression, after primary
analysis one was confirmed to have partial response (not progression),
for a total of two DFS events. <sup>b</sup>At 12 cycles after random
assignment. DFS, disease-free survival; MRD, minimal residual disease;
uMRD, undetectable minimal residual disease.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g006.jpg" />
          </fig>
          <p>Median treatment duration across the overall study period was 31.3 months (range,
19.4-37.0 months) in the placebo arm and 31.3 months (range, 20.3-39.8 months)
in the ibrutinib arm (Data Supplement). AEs of any grade generally decreased in
prevalence over time after random assignment (Fig <xref rid="fig5" ref-type="fig">5</xref>A). Prevalence of grade ≥ 3 AEs also decreased
before and after random assignment, with a greater reduction in the placebo arm
(Fig <xref rid="fig5" ref-type="fig">5</xref>B). Diarrhea and neutropenia were
less prevalent with placebo versus ibrutinib before and after random assignment
and decreased over time in both arms (Figs <xref rid="fig5" ref-type="fig">5</xref>A and <xref rid="fig5" ref-type="fig">5</xref>B).</p>
          <fig position="float" id="fig5" fig-type="figure" orientation="portrait">
            <label>FIG 5.</label>
            <caption>
              <p>Rates over time of AEs of clinical interest. (A) Prevalence of AEs of
clinical interest over time by randomized treatment arm for any-grade
AEs and (B) grade ≥ 3 AEs. <sup>a</sup>At postrandomization 7-12
months, Confirmed uMRD population: placebo (n = 42), ibrutinib (n
= 42); uMRD Not Confirmed population: ibrutinib (n = 30),
ibrutinib plus venetoclax (n = 29). <sup>b</sup>Grade 3 menorrhagia
in one patient. <sup>c</sup>Grade 3 retroperitoneal hemorrhage in one
patient. AEs, adverse events; uMRD, undetectable minimal residual
disease. </p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g007.jpg" />
          </fig>
        </sec>
        <sec>
          <title>Randomized Phase: Efficacy and Safety in uMRD Not Confirmed
Population</title>
          <p>Estimated 30-month PFS rates in the uMRD Not Confirmed population were 95% (95%
CI, 71 to 99) with ibrutinib and 97% (95% CI, 79 to 100) with ibrutinib plus
venetoclax (Data Supplement). Approximately half of the patients who achieved a
best response of PR prerandomization converted to CR including CRi with further
ibrutinib (8 of 15) or ibrutinib plus venetoclax (10 of 24) (Data Supplement).
With randomized treatment, the proportion of patients with best response of uMRD
remained relatively unchanged at 45% in PB but improved from 32% to 42% in BM
with ibrutinib, and from 50% to 69% in PB and from 31% to 66% in BM with
ibrutinib plus venetoclax (Fig <xref rid="fig6" ref-type="fig">6</xref>).</p>
          <fig position="float" id="fig6" fig-type="figure" orientation="portrait">
            <label>FIG 6.</label>
            <caption>
              <p>Best overall uMRD rates by randomized treatment arm in the uMRD Not
Confirmed population. BM, bone marrow; PB, peripheral blood; uMRD,
undetectable minimal residual disease.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-39-3853-g008.jpg" />
          </fig>
          <p>Median treatment duration across the overall study period was 31.2 months (range,
17.8-36.6 months) in the ibrutinib arm and 29.2 months (range, 15.4-36.9 months)
in the ibrutinib plus venetoclax arm (Data Supplement). In the uMRD Not
Confirmed population, the prevalence of grade ≥ 3 AEs was higher with
ibrutinib plus venetoclax than with ibrutinib during months 7-12
postrandomization (Fig <xref rid="fig5" ref-type="fig">5</xref>B). The
prevalence of infections increased postrandomization in both arms (Fig <xref rid="fig5" ref-type="fig">5</xref>A). One grade 5 AE (sudden cardiac death)
occurred in the ibrutinib arm during cycle 32.</p>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>DISCUSSION</title>
        <p>First-line treatment with three cycles of single-agent ibrutinib followed by 12
cycles of combined ibrutinib plus venetoclax provided deep remissions, as evidenced
by attainment of uMRD in over two-thirds of patients with CLL or SLL, including high
BM uMRD rates in those with high-risk disease features, such as del(17p) or
<italic toggle="yes">TP53</italic> mutation, del(11q), and unmutated IGHV gene. Overall, best
uMRD rates were high in both BM (68%) and PB (75%), and compartmental concordance
was 94%. These findings are consistent with preclinical synergistic antitumor
activity between ibrutinib and venetoclax.<sup>
            <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b14" ref-type="bibr">14</xref>
          </sup>
        </p>
        <p>Given the lack of information on PFS outcomes after FD treatment with ibrutinib or
venetoclax at the time of study design, a strict definition of Confirmed uMRD was
used to ensure equipoise for placebo-randomly assigned patients. For patients who
achieved Confirmed uMRD in PB and BM with ibrutinib plus venetoclax
prerandomization, rates of DFS 1 year after random assignment to placebo or
ibrutinib were comparable at 95% and 100%, respectively, suggesting that ibrutinib
can be discontinued in the setting of a deep response with minimal risk of early
relapse during the first year after discontinuation. The proportion of patients with
uMRD in PB at 12 cycles postrandomization was comparable with placebo or ibrutinib;
the majority (84%) of placebo patients still had uMRD through the first year after
discontinuing active CLL treatment, supporting the potential for durable,
treatment-free remissions with FD ibrutinib plus venetoclax.</p>
        <p>PFS rates at 30 months were ≥ 95% across all four treatment arms in this
population of young, fit patients. Taking patient population differences into
account, and pending confirmation in the phase III setting, these rates appear to
compare favorably with 3-year PFS rates reported with FCR (73%), continuous
ibrutinib combined with rituximab (89%), and FD venetoclax plus obinutuzumab
(82%).<sup>
            <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b9" ref-type="bibr">9</xref>
          </sup> Longer follow-up and results from the CAPTIVATE FD
cohort and ongoing randomized phase III study comparing FD ibrutinib plus venetoclax
to chlorambucil plus obinutuzumab (GLOW, <ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT03462719" ext-link-type="uri">NCT03462719</ext-link>) will help answer important remaining questions
regarding time-limited treatment with this promising combination, including
durability, efficacy in patients with high-risk genomic features, and
characteristics of patients most suitable to receive time-limited versus continuous
treatment with ibrutinib. Observed high CR and uMRD rates may translate into even
longer-term PFS.<sup>
            <xref rid="b21" ref-type="bibr">21</xref>
          </sup>
        </p>
        <p>uMRD rates are consistent with those previously reported with ibrutinib plus
venetoclax (61% in BM after 12 cycles) in first-line CLL,<sup>
            <xref rid="b29" ref-type="bibr">29</xref>
          </sup> and higher than those reported with single-agent
ibrutinib (≤ 10% in both PB and BM)<sup>
            <xref rid="b30" ref-type="bibr">30</xref>,<xref rid="b31" ref-type="bibr">31</xref>
          </sup> or single-agent
venetoclax (PB, 27%; BM, 16% in relapsed or refractory patients).<sup>
            <xref rid="b5" ref-type="bibr">5</xref>-<xref rid="b8" ref-type="bibr">8</xref>
          </sup> uMRD rates also compare favorably with first-line CLL
treatments, such as ibrutinib plus obinutuzumab (PB, 30%; BM, 20%),<sup>
            <xref rid="b32" ref-type="bibr">32</xref>
          </sup> FCR (PB, 59%-63%; BM,
43%),<sup>
            <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b21" ref-type="bibr">21</xref>-<xref rid="b23" ref-type="bibr">23</xref>
          </sup>
venetoclax plus obinutuzumab (PB, 76%; BM, 57%),<sup>
            <xref rid="b9" ref-type="bibr">9</xref>
          </sup> and ibrutinib plus venetoclax plus obinutuzumab (67% in both
PB and BM),<sup>
            <xref rid="b33" ref-type="bibr">33</xref>
          </sup> particularly for MRD
eradication in BM. The results from the postrandomization phase add to the body of
evidence correlating depth of response (uMRD and CR) with survival outcomes, with
similar changes in uMRD and CR status in patients receiving further treatment with
placebo or ibrutinib after 12 cycles of ibrutinib plus venetoclax. Greater
improvements in uMRD rates are seen in patients with uMRD Not Confirmed status
receiving further treatment with ibrutinib plus venetoclax. Additional follow-up
will elucidate the impact of further treatment with ibrutinib or ibrutinib plus
venetoclax on long-term outcomes, such as PFS.</p>
        <p>Reductions in TLS risk category through effective debulking before venetoclax
initiation have the potential to improve convenience for patients, caregivers, and
health care providers and increase the ease of venetoclax administration. In the
CLL14 study, no TLS was noted during venetoclax initiation after initial treatment
with obinutuzumab; however, TLS occurred during obinutuzumab lead-in.<sup>
            <xref rid="b34" ref-type="bibr">34</xref>
          </sup> Three cycles of single-agent
ibrutinib reduced TLS risk category in 90% of patients with high baseline TLS risk
and only 2% remained categorized with high risk before initiation of venetoclax
ramp-up. TLS risk category reduction was primarily attributable to rapid reductions
in lymph node bulk with single-agent ibrutinib as predicted by earlier
studies.<sup>
            <xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b29" ref-type="bibr">29</xref>
          </sup> Consequently, the frequency with which
hospitalization was indicated for TLS monitoring decreased by more than half (from
47% to 18%) after ibrutinib lead-in. Moreover, rasburicase use for TLS prophylaxis
(6%) was lower than that reported with single-agent venetoclax (27%-45%).<sup>
            <xref rid="b35" ref-type="bibr">35</xref>,<xref rid="b36" ref-type="bibr">36</xref>
          </sup>
        </p>
        <p>The safety profile of ibrutinib plus venetoclax was consistent with known AEs for
each agent alone, with no new safety signals observed. Diarrhea and neutropenia
infrequently led to dose modifications or treatment discontinuation. Rates of grade
≥ 3 diarrhea were somewhat higher than expected with ibrutinib alone but were
similarly low (≤ 5%) as with continuous ibrutinib plus rituximab or
FCR,<sup>
            <xref rid="b3" ref-type="bibr">3</xref>
          </sup> venetoclax plus
obinutuzumab,<sup>
            <xref rid="b9" ref-type="bibr">9</xref>
          </sup> or ibrutinib
plus venetoclax plus obinutuzumab.<sup>
            <xref rid="b33" ref-type="bibr">33</xref>
          </sup> Rates of grade ≥ 3 neutropenia (35%) were higher than
continuous ibrutinib plus rituximab (26%)<sup>
            <xref rid="b3" ref-type="bibr">3</xref>
          </sup> but lower than FCR (45%),<sup>
            <xref rid="b3" ref-type="bibr">3</xref>
          </sup> venetoclax plus obinutuzumab (53%),<sup>
            <xref rid="b9" ref-type="bibr">9</xref>
          </sup> or ibrutinib plus venetoclax plus
obinutuzumab (56%).<sup>
            <xref rid="b33" ref-type="bibr">33</xref>
          </sup> AEs led to
discontinuation of ibrutinib and/or venetoclax in 7% of patients prerandomization,
compared with 11% and 24% with ibrutinib plus rituximab and FCR, respectively, in
ECOG1912<sup>
            <xref rid="b3" ref-type="bibr">3</xref>
          </sup> and 16% with
venetoclax plus obinutuzumab in CLL14.<sup>
            <xref rid="b9" ref-type="bibr">9</xref>
          </sup>
        </p>
        <p>Frequencies of new or ongoing AEs were generally highest during the first 6 months of
prerandomization treatment with ibrutinib plus venetoclax and then decreased over
time irrespective of randomized arms. A slightly higher prevalence of infections was
observed postrandomization in the uMRD Not Confirmed population than in the
Confirmed uMRD population, suggesting that prevalence of infections may be
influenced by disease status. Postrandomization treatment with ibrutinib plus
venetoclax was associated with higher prevalence of grade ≥ 3 AEs, any-grade
neutropenia, and any-grade diarrhea than placebo or continued ibrutinib. Thus, the
benefit of improved uMRD and CR rates with continued ibrutinib plus venetoclax needs
to be weighed against the risk of increased or ongoing toxicities.</p>
        <p>In conclusion, the ibrutinib plus venetoclax combination for first-line treatment of
patients with CLL or SLL represents an all-oral, once-daily, chemotherapy-free
regimen that provides high rates of uMRD in both BM and PB. The 1-year DFS rate of
95% in patients with Confirmed uMRD randomly assigned to placebo following 12 cycles
of combined ibrutinib plus venetoclax and 30-month PFS rates of ≥ 95% across
MRD-guided randomized treatment arms suggest the potential for FD treatment with
this combination, which may provide physicians with the ability to continue to
select ibrutinib-based therapy (continuous or fixed) in the outpatient setting while
considering patient preferences and treatment goals. Fixed duration is being
evaluated in the younger population of patients in the CAPTIVATE FD cohort and in a
complementary elderly or unfit population in the ongoing phase III GLOW study.</p>
      </sec>
    </body>
  </article>
</pmc-articleset>